CymaBay Therapeutics (CBAY) Scheduled to Post Earnings on Wednesday

CymaBay Therapeutics (NASDAQ:CBAY) will announce its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter.

CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.04. On average, analysts expect CymaBay Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of CBAY stock opened at $13.08 on Tuesday. CymaBay Therapeutics has a 52 week low of $6.31 and a 52 week high of $15.00. The firm has a market capitalization of $901.27 million, a P/E ratio of -10.38 and a beta of 1.77.

A number of analysts recently commented on CBAY shares. Piper Jaffray Companies set a $30.00 price target on CymaBay Therapeutics and gave the stock a “buy” rating in a research note on Friday, March 1st. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $20.00 price target on shares of CymaBay Therapeutics in a research note on Friday, February 1st. Roth Capital reaffirmed a “buy” rating on shares of CymaBay Therapeutics in a research note on Tuesday, February 19th. Oppenheimer set a $18.00 price target on CymaBay Therapeutics and gave the stock a “buy” rating in a research note on Friday, February 15th. Finally, BidaskClub raised CymaBay Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, February 27th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $19.38.

In other CymaBay Therapeutics news, Director Carl Goldfischer sold 11,675 shares of the firm’s stock in a transaction on Thursday, February 7th. The stock was sold at an average price of $9.02, for a total transaction of $105,308.50. Following the completion of the transaction, the director now owns 2,335 shares of the company’s stock, valued at $21,061.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.50% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

See Also: Put Option Volume

Earnings History for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with's FREE daily email newsletter.